Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
July 24, 2025 10:01 AM 4 min read

Earnings Outlook For Centene

by Benzinga Insights Benzinga Staff Writer
Follow

Centene (NYSE:CNC) is set to give its latest quarterly earnings report on Friday, 2025-07-25. Here's what investors need to know before the announcement.

Analysts estimate that Centene will report an earnings per share (EPS) of $0.41.

Anticipation surrounds Centene's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Performance in Previous Earnings

In the previous earnings release, the company beat EPS by $0.36, leading to a 0.0% drop in the share price the following trading session.

Here's a look at Centene's past performance and the resulting price change:

Quarter Q1 2025 Q4 2024 Q3 2024 Q2 2024
EPS Estimate 2.54 0.49 1.38 2.07
EPS Actual 2.90 0.80 1.62 2.42
Price Change % -6.0% -1.0% 4.0% 8.0%

Performance of Centene Shares

Shares of Centene were trading at $29.42 as of July 23. Over the last 52-week period, shares are down 60.68%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

Analyst Opinions on Centene

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Centene.

Analysts have given Centene a total of 16 ratings, with the consensus rating being Neutral. The average one-year price target is $49.62, indicating a potential 68.66% upside.

Analyzing Analyst Ratings Among Peers

The analysis below examines the analyst ratings and average 1-year price targets of Molina Healthcare, HealthEquity and Alignment Healthcare, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.

Summary of Peers Analysis

Within the peer analysis summary, vital metrics for Molina Healthcare, HealthEquity and Alignment Healthcare are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

Key Takeaway:

Centene ranks in the middle among its peers for revenue growth. It is at the bottom for gross profit and return on equity.

About Centene

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.

Unraveling the Financial Story of Centene

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Centene's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 15.38%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 2.81%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Centene's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.83%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Centene's ROA excels beyond industry benchmarks, reaching 1.55%. This signifies efficient management of assets and strong financial health.

Debt Management: Centene's debt-to-equity ratio is below the industry average at 0.66, reflecting a lower dependency on debt financing and a more conservative financial approach.

To track all earnings releases for Centene visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
EarningsBZI-EP
CNC Logo
CNCCentene Corp
$42.843.90%
Overview
  • Analysts currently favor an Neutral trajectory for Molina Healthcare, with an average 1-year price target of $321.38, suggesting a potential 992.39% upside.
  • Analysts currently favor an Outperform trajectory for HealthEquity, with an average 1-year price target of $116.88, suggesting a potential 297.28% upside.
  • Analysts currently favor an Neutral trajectory for Alignment Healthcare, with an average 1-year price target of $17.0, suggesting a potential 42.22% downside.
Company Consensus Revenue Growth Gross Profit Return on Equity
Centene Neutral 15.38% $5.20B 4.83%
Molina Healthcare Neutral 12.24% $1.28B 6.77%
HealthEquity Outperform 15.04% $224.31M 2.54%
Alignment Healthcare Neutral 47.46% $106.03M -8.76%
CNC Logo
CNCCentene Corp
$42.843.90%
Overview
Comments
Loading...